Biomedical subjects

Esther A Coors

Publications and source records attributed to Esther A Coors.

5 recordsLinked to original sources

PubMed2005

Polysorbate 80 in medical products and nonimmunologic anaphylactoid reactions.

BACKGROUND: Polyoxyethylene-sorbitan-20-monooleate (also known as polysorbate 80 and Tween 80) is a solubilizing agent ubiquitously used in nutritives, creams, ointments, lotions, and multiple medical preparations (e.g., vitamin oils, vaccines, and anticancer agents) and as an additive in tablets. Whereas its relevance as a contact allergen has declined during the past decades, it is of current relevance as a "hidden" inductor of anaphylactoid reactions. OBJECTIVE: To identify polysorbate 80 (generally believed to be an inert vehicle) as an inductor of a severe anaphylactoid reaction. METHODS: Skin prick testing, enzyme-linked immunosorbent assay, IgE immunoblotting, and flow cytometric detection of basophil activation were performed in controls and in a patient with a medical history of anaphylactic shock due to intravenous administration of a multivitamin product during pregnancy. RESULTS: Polysorbate 80 was identified as the causative agent for the anaphylactoid reaction of nonimmunologic origin in the patient. Polysorbate specific IgE antibodies were not identified in enzyme-linked immunosorbent assay and immunoblot examinations, confirming the nonimmunologic nature of the anaphylactoid reaction. CONCLUSIONS: Polysorbate 80 is a ubiquitously used solubilizing agent that can cause severe nonimmunologic anaphylactoid reactions.

Anaphylaxis↗

PubMed2004

Topical photodynamic therapy for patients with therapy-resistant lesions of cutaneous T-cell lymphoma.

Photodynamic therapy after topical application of 5-aminolevulinic acid is an effective therapy for nonmelanoma epithelial skin cancers. It has also been used for some cases of cutaneous T-cell lymphoma. We treated 4 patients with different cutaneous T-cell lymphomas with photodynamic therapy. Those patients had previously reached a partial remission with more conventional therapies, but single lesions had remained. In all of these cases a complete remission of these lesions was achieved. We, therefore, suggest that photodynamic therapy can be a useful additional treatment modality for patients with therapy-resistant lesions of cutaneous T-cell lymphoma.

Administration, Topical↗

PubMed2002

Bilateral temporal arteritis.

Temporal arteritis is a giant cell arteritis that affects large- or medium-sized elastic arteries. Often, only 1 temporal artery is affected. We describe a patient with both temporal arteries being involved simultaneously. To our knowledge, this particular constellation has rarely been described so far.

Aged↗

PubMed2002

Localized cutaneous small to medium-sized pleomorphic T-cell lymphoma: a report of 3 cases stable for years.

Small to medium-sized pleomorphic cutaneous T-cell lymphomas represent a provisional entity in the new European Organization for Research and Treatment of Cancer classification. We describe 3 patients with a localized and outstanding stable variant of this tumor. A median follow-up period of 50 months did not reveal any spread into regional lymph nodes or to distant sites in any patient.

Adult↗

PubMedDate not supplied

Topical imiquimod as treatment for different kinds of cutaneous lymphoma.

Imiquimod as a topical immune response modifier leads to a localized production of interferon and other cytokines. Apart from its use for genital warts it has therefore been used as treatment for different cutaneous neoplasms, including a few cases of cutaneous T-cell lymphoma. We treated 8 patients (4 with mycosis fungoides, 1 with CD30+ anaplastic large cell lymphoma and 3 with primary cutaneous B-cell lymphoma) with topical imiquimod. Therapy was started three times per week, in cases without response, the frequency was increased to a daily application. Two patients with mycosis fungoides and the patient with the CD30+ anaplastic large cell lymphoma had a complete clinical remission, the other two patients with mycosis fungoides did not show a response to imiquimod. Of the patients with cutaneous B-cell lymphoma, two reached a partial remission, one did not respond to therapy. Two patients had side effects such as erythema and pruritus which disappeared when the frequency of therapy was reduced. Our preliminary data show that imiquimod might be effective in some cases with therapy resistant lesions of cutaneous T-cell lymphoma as well as of cutaneous B-cell lymphoma, but more controlled studies are needed.

Administration, Topical↗